Organon (OGN) Proxy filing summary

Executive summary

• Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in cash, representing a 103% premium to the unaffected share price and an enterprise value of $11.75 billion.

• The transaction is structured as a merger, with Organon becoming a wholly owned subsidiary of Sun Pharma, and is expected to close in early 2027, subject to regulatory and shareholder approvals.

• The combined company will be among the top 25 global pharmaceutical firms, with a strong presence in women's health, biosimilars, and established brands, and projected combined revenue of $12.4 billion.

• Organon shareholders will receive cash consideration, and all equity awards will be treated per the merger agreement, with options, RSUs, and PSUs either paid out or converted to cash-based awards.

• The Boards of both companies have approved the transaction, and Sun Pharma has secured committed debt financing to fund the acquisition and refinance Organon's existing debt.

Voting matters and shareholder proposals

• The merger requires approval by a majority of Organon shareholders at a duly called meeting.

• A proxy statement will be filed and mailed to shareholders, who are urged to read all relevant documents.

• The agreement includes a “no-shop” provision, but allows the board to consider superior proposals under certain conditions.

• If the board changes its recommendation or accepts a superior proposal, a $120 million termination fee is payable to Sun Pharma.

Board of directors and corporate governance

• The board of directors of Organon has approved the merger and recommended it to shareholders.

• Upon closing, the board of the surviving corporation will be comprised of the directors of the merger subsidiary.

• Recent executive appointments include Joseph Morrissey as permanent CEO and Carrie S. Cox as Executive Chair, with no changes to their compensation.